Pharmacotherapy of obesity

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 6, 1997, Pages 407-411

  Mezitis, Spyros G E ^a   Aronne, Louis J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013627093     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199712000-00005     Document Type: Article

References (22)

1. American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE): Obesity statement Endocr Pract 1997, 3:165-208. This important document provides physicians and associates with guidance on the ways in which obesity can be treated and the procedures for selecting patients for these treatments.
2. Shape Up America! and the American Obesity Association: Guidance for Treatment of Adult Obesity. Chicago: American Obesity Association; 1996. This joint public health initiative outlines a comprehensive weight reduction program in an attempt to reverse the upward trend in obesity and obesity-related disease rates.
3. Kuczmarski RJ, Regal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight among US adults: the National Hearth and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994, 272:205-211.
4. Centers for Disease Control and Prevention: Update: prevalence of overweight among children, adolescents and adults-United States, 1988-1994. MMWR Morb Mortal Wkly Rep 1997, 46:199-202.
5. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy In the management of obesity. JAMA 1996, 276:1907-1915. This review examines published scientific information on the safety and efficacy of antiobesity drugs used continuously for more than 24 weeks. It concludes that pharmacotherapy helps some obese individuals lose weight and maintain weight loss for at least 1 year but cannot be recommended for routine use.
6. Balsiger BM, Luque-de-Leon E, Sarr MG: Surgical treatment of obesity: who is an appropriate candidate? Mayo Clin Proc 1997, 72:551-558.
7. Campfield LA, Smith FJ, Bum P: OB protein: a hormonal controller of central neural networks mediating behavioral, metabolic and neuroendocrine responses. Endocrinol Metab 1997, 4:81-102.
8. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee U, Bauer TL, Caro JF: Serum Immunoreactive-leptin concentrations In normal-weight and obese humans. W Engt J Med 1996, 334:292-295.
9. Bray GA. Ryan DH: Drugs used in the treatment of obesity. Diabetes Rev 1997, 5:83-103. An excellent updated guide to current and potential drugs used for the treatment of obesity.
10. Fujioka K: Medical management of obesity. Hosp Med 1996, 32:28-35.
11. Aronne LJ, Vargas I: Evaluation and treatment of the obese patient Hosp Med, in press.
12. Drent ML, van der Veerj EA: Llpase Inhibition: a novel concept In the treatment of obesity. Int J Obes 1993, 17:241-244.
13. Weber C, Tam YK, Schmidtke-Schrezenmeier G, Jonkmann JHG, van Brummelen P: Effect of the lipase Inhibitor orlistat on the pharmacoklnetics of four different antihypertensive drugs In healthy volunteers. Eur J Clin Pharmacol 1996, 51:87-90.
14. Jones SP, Smith IG, Kelly F, Gray JA: Long-term weight loss with sibutramine. Int J Obes 1995, 19(suppl 2):41.
15. Lean MEI: Sibutramine - a review of clinical efficacy. Int J Obes 1997, 21(suppl):S30-S36.
16. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR: Fluoxetine: a randomized clinical trial In the treatment of obesity. Int J Obes 1994, 18:129-135.
17. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996, 335:609-616.
18. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA: Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. JAMA 1997, 278:666-672.
19. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
20. Graham DJ, Green L: Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:635.
21. Cannistra LB, Davis SM, Bauman AG: Valvular heart disease associated with dexfenfluramine. W Engl J Med 1997, 337:636.
22. Cincotta AH, Meier AH: Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996, 19:667-670.